Difference between revisions of "Asparaginase (Elspar)"
m |
|||
Line 24: | Line 24: | ||
[[Category:Enzymes]] | [[Category:Enzymes]] | ||
[[Category:Acute lymphocytic leukemia medications]] | [[Category:Acute lymphocytic leukemia medications]] | ||
+ | [[Category:T-cell lymphoma medications]][[Category:Drugs FDA approved in 1978]] |
Revision as of 21:21, 5 November 2014
General information
Class/mechanism: Depletes plasma asparagine, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase.[1][2]
Route: IV, IM
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Asparaginase (Elspar) patient drug information (Chemocare)[3]
- Asparaginase (Elspar) patient drug information (UpToDate)[4]
Also known as
Asparaginasa, Asparaginase Medac, Chephacardin, Colaspase, Crasnitin, Elspar, Erwina Asparaginas, Erwinase, Erwinaze, Erwinia, Erwiniase, Kidrolase, L-ASP, L-Asparaginasa Filaxis, Laspar, L Asparaginasa, L Asparaginase, L Asparaginasum, Leucoginase, Leunase, Paronal